News|Articles|April 8, 2025

Q1 2025 Recap: Ophthalmology News and Updates

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

Ophthalmology in Q1 2025 saw pivotal advancements across the regulatory, clinical, and innovation landscapes. Updates from the US Food and Drug Administration (FDA) marked progress in treatment delivery, long-term disease management, and first-in-class approvals, while late-stage trial data signaled shifting paradigms for chronic retinal diseases and neuroprotective strategies.

Related to this article

October 8th, 2026

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.

October 8th, 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

October 8th, 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

October 8th, 2026

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.